Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 2/20 | 0.37 |
| ▸ | CPT1A | P50416 | 3/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 10/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587926 | 0.92 | SCN9A (0.33) | CPT1ACPT2 | |
| SCHEMBL3634133 | 0.87 | CPT1A (0.31) | CPT1ACPT2 | |
| SCHEMBL3591381 | 0.85 | SCN9A (0.33) | CPT1ACPT2 | |
| SCHEMBL3581541 | 0.83 | CPT1A (0.34) | CPT1ACPT2KDM4EALDH1A1 | |
| SCHEMBL3590433 | 0.79 | TRPC3 (0.40) | EIF4ECPT1ACPT2CCR2KDM4E | |
| SCHEMBL3588558 | 0.79 | PTGS1 (0.37) | — | |
| SCHEMBL3586297 | 0.73 | ALDH1A1 (0.43) | EIF4ECPT1ACPT2KDM4EMEN1 | |
| SCHEMBL3580394 | 0.71 | TRPC3 (0.44) | CPT1ACPT2KDM4ELMNAHTT | |
| SCHEMBL3587927 | 0.71 | ALDH1A1 (0.38) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3594582 | 0.69 | RHOC (0.39) | CPT1ACPT2KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | EIF4E 3717/4885CPT1A 1947/4885CPT2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.